School of Medicine
Medical tablets, capsules and caplets flying out of a bottle against a light blue background

People

Image of Abhik Mukherjee

Abhik Mukherjee

Clinical Associate Professor Histopathology, Faculty of Medicine & Health Sciences

Contact

Biography

Dr Mukherjee studied Medicine and trained in Radiation Oncology at Calcutta University; and thereafter completed an MSc and PhD in Oncology from the University of Nottingham. He subsequently trained in Histopathology at Leicester and Nottingham, where he was an NIHR Academic Clinical Fellow and Lecturer. After attaining his FRCPath (Histopathology) by exam in 2015, he is currently a Clinical Associate Professor (Honorary Consultant) at Nottingham University and Nottingham University Hospitals NHS Trust.

His research interests are molecular characterisation of lympho-vascular invasion in cancers, low grade breast cancer biology and biomarkers in inflammatory bowel disease. He has held project grants from Cancer Research UK, Academy of Medical Sciences and the Pathological Society and has had the privilege of working on prestigious collaborative projects [METABRIC: Molecular Taxonomy of the Breast Cancer International Consortium], clinical trials [NEOTANGO, SCOTROC/TRANSCOTROC] and industry led computational pathology initiatives [Optimata, Israel and Barco, Belgium].

He is currently co-leading the development of the MSc in Molecular Pathology for the Nottingham Molecular Pathology Node (Work Stream 9) and also sits on the NCRI-CMPath Clinical Trials Pathology Advisory Group (CT-PAG) and educational subcommittee of the Pathological Society of Great Britain and Ireland.

He holds several peer-reviewed publications and has presented his research at National and International Conferences with several bursaries/awards from the British Association of Cancer Research, British MicroCirculation Society and the Cancer Research UK.

Expertise Summary

Dr Mukherjee's current interests are in colorectal and breast cancer pathology and biomarkers/molecular signatures of metastases and response to therapy. He has extensive experience of breast, ovarian and colorectal cancer research. This includes molecular/immunological markers of prognosis and prediction of response to therapeutic agents. He has also a strong background in researching the mechanism of action of novel drugs (including anti-angiogenic agents) and validation of drug targets used in cancer therapy. He is also interested in inflammatory bowel diseases especially novel molecular techniques aiding pathological diagnosis.

Selected Publications

  • QAISER T, MUKHERJEE A, REDDY PB C, MUNUGOTI SD, TALLAM V, PITKÄAHO T, LEHTIMÄKI T, NAUGHTON T, BERSETH M, PEDRAZA A, MUKUNDAN R, SMITH M, BHALERAO A, RODNER E, SIMON M, DENZLER J, HUANG CH, BUENO G, SNEAD D, ELLIS IO, ILYAS M and RAJPOOT N, 2018. Her2 Challenge Contest: A Detailed Assessment of Automated Her2 Scoring Algorithms in Whole Slide Images of Breast Cancer Tissues. Histopathology. 72(2), 227-238
  • ALESKANDARANY MA, SONBUL S, SURRIDGE R, MUKHERJEE A, CALDAS C, DIEZ-RODRIGUEZ M, ASHANKYTY I, ALBRAHIM KI, ELMOUNA AM, ANEJA R, MARTIN SG, ELLIS IO, GREEN AR and RAKHA EA, 2018. Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. British journal of cancer. 117(8), 1176-1184
  • CHRYSANTHOU E, GORRINGE KL, JOSEPH C, CRAZE M, NOLAN CC, DIEZ-RODRIGUEZ M, GREEN AR, RAKHA EA, ELLIS IO and MUKHERJEE A, 2017. Phenotypic characterisation of breast cancer: the role of CDC42. Breast cancer research and treatment.
  • SONBUL SN, GORRINGE KL, ALESKANDARANY MA, MUKHERJEE A, GREEN AR, ELLIS IO and RAKHA EA, 2017. Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. The journal of pathology. Clinical research. 3(2), 105-114
  • MILIGY I, MOHAN P, GABER A, ALESKANDARANY MA, NOLAN CC, DIEZ-RODRIGUEZ M, MUKHERJEE A, CHAPMAN C, ELLIS IO, GREEN AR and RAKHA EA, 2017. Prognostic significance of Tumour infiltrating B-Lymphocytes in Breast Ductal Carcinoma in Situ. Histopathology. 71(2), :258-268
  • PEREIRA B, CHIN SF, RUEDA OM, VOLLAN HK, PROVENZANO E, BARDWELL HA, PUGH M, JONES L, RUSSELL R, SAMMUT SJ, TSUI DW, LIU B, DAWSON SJ, ABRAHAM J, NORTHEN H, PEDEN JF, MUKHERJEE A, TURASHVILI G, GREEN AR, MCKINNEY S, OLOUMI A, SHAH S, ROSENFELD N, MURPHY L, BENTLEY DR, ELLIS IO, PURUSHOTHAM A, PINDER SE, BØRRESEN-DALE AL, EARL HM, PHAROAH PD, ROSS MT, APARICIO S and CALDAS C, 2016. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nature communications. 7, 11479
  • JOSEPH, C., RUSSELL, R., CRAZE, M., NOLAN, C., PROVENZANO, E., CALDAS, C., GREEN, A., RAKHA, E., ELLIS, I. O. and MUKHERJEE, A., 2016. The Prognostic Significance of KRAS-Induced Actin-Interacting Protein (KRAP) Expression in Invasive Breast Cancer JOURNAL OF PATHOLOGY. 240, 16-16
  • SONBUL, S. N., PIGERA, M., MUKHERJEE, A., ALESKANDARANY, M. A., GREEN, A. R., DIEZ-RODRIGUEZ, M., JOSEPH, C., NOLAN, C. C., ELLIS, I. O. and RAKHA, E. A., 2016. Ankyrin 3 Protein may Influence DNA-Damage Response Pathways and the Immune Response in Invasive Breast Carcinoma JOURNAL OF PATHOLOGY. 240, 19-19
  • SONBUL, S. N., MUKHERJEE, A., RUSSELL, R., RUEDA, O. M., ALESKANDARANY, M. A., GREEN, A. R., NOLAN, C. C., DIEZ-RODRIGUEZ, M., PROVENZANO, E., CALDAS, C., ELLIS, I. O. and RAKHA, E. A., 2016. Multiple Coagulation Factor Deficiency Protein-2 (MCFD2) as a Potential Prognostic Germ Cell Marker in Invasive Breast Carcinoma: a Transcriptome-Driven Study JOURNAL OF PATHOLOGY. 240, 21-21
  • MILIGY, I., GABER, A., MOHAN, P., NOLAN, C., DIEZ-RODRIGUEZ, M., CRAZE, M., JOSEPH, C., AL-KAABI, M. M., ALESKANDARANY, M. A., MUKHERJEE, A., CHAPMAN, C., MACMILLAN, R. D., ELLIS, I. O., GREEN, A. R. and RAKHA, E. A., 2016. Prognostic Significance of Tumour Infiltrating Lymphocytes in Ductal Carcinoma In Situ JOURNAL OF PATHOLOGY. 240, 26-26
  • BARUS, N., JOSEPH, C., CRAZE, M., ALIYEVA, T., OJIEGBE, S., NOLAN, C., DIEZ-RODRIGUEZ, M., GREEN, A. R., RAKHA, E., ELLIS, I. O. and MUKHERJEE, A., 2016. Loss of Latent MMP7 Leads to Increased Lympho-Vascular Invasion and Poor Prognosis in Breast Cancer JOURNAL OF PATHOLOGY. 240, 26-26
  • CRAZE, M., JOSEPH, C., RUSSELL, R., RUEDA, O. M., PROVENZANO, E., CALDAS, C., GREEN, A. R., RAKHA, E., ELLIS, I. O. and MUKHERJEE, A., 2016. Phosphorylation Status of MED1 Protein Results in Differential Prognosis in Breast Cancer JOURNAL OF PATHOLOGY. 240, 26-26
  • BARUS, N., JOSEPH, C., CRAZE, M., PROVENZANO, E., RUSSELL, R., CALDAS, C., GREEN, A. R., RAKHA, E., ELLIS, I. O. and MUKHERJEE, A., 2016. Investigating the Role of CREM Protein in Lymphovascular Invasion in Breast Cancer JOURNAL OF PATHOLOGY. 240, 26-26
  • SONBUL, S. N., MUKHERJEE, A., ALESKANDARANY, M. A., RUSSELL, R., RUEDA, O., GREEN, A. R., NOLAN, C. C., DIEZ-RODRIGUEZ, M., PROVENZANO, E., CALDAS, C., ELLIS, I. O. and RAKHA, E. A., 2016. Vesicular Transporter Proteins in Invasive Breast Cancer: Clinicopathological Relevance of Synaptosomal-Associated Protein-23 (SNAP23) JOURNAL OF PATHOLOGY. 240, 15-15
  • HAMARSHEH, S., CRAZE, M., JOSEPH, C., PROVENZANO, E., RUSSELL, R., CALDAS, C., GREEN, A. R., RAKHA, E., ELLIS, I. O. and MUKHERJEE, A., 2016. Nostrin as a Marker Related to Low Grade and Better Prognosis in Breast Cancer JOURNAL OF PATHOLOGY. 240, 20-20
  • SONBUL, S. N., ALESKANDARANY, M. A., MUKHERJEE, A., GREEN, A. R., MILIGY, I., DIEZ-RODRIGUEZ, M., NOLAN, C. C., ELLIS, I. O. and RAKHA, E. A., 2016. Clinicopathological Impact of C-C Chemokine Receptor Type 7 (CCR7) Protein Expression in Triple Negative Breast Carcinoma (TNBC) JOURNAL OF PATHOLOGY. 240, 27-27
  • JOSEPH, C., CRAZE, M., NOLAN, C., DIEZ-RODRIGUEZ, M., GREEN, A. R., RAKHA, E., ELLIS, I. O. and MUKHERJEE, A., 2016. Subcellular Localisation Specific HOXB13:IL17BR Protein Index Predicts For Poorer Prognosis and Metastatic Progression in Breast Cancer JOURNAL OF PATHOLOGY. 240, 25-25
  • MARCHESSOUX, C., KAYE, P. V., MUKHERJEE, A., PAINE, S., HAIDER, A. and ILYAS, M., 2016. Digital Microscopy is Non-inferior to Optical Microscopy in the Diagnosis of Dysplasia in Barrett's Oesophagus: A Validation Study JOURNAL OF PATHOLOGY. 240, 19-19
  • CHRYSANTHOU, E., JOSEPH, C., CRAZE, M., SORIA, D., ELLIS, I. O. and MUKHERJEE, A., 2015. Phenotyping Characterisation of Breast Cancers: the Role of CDC Proteins (2, 42 & 42BPB) JOURNAL OF PATHOLOGY. 237, S31-S31
  • SONBUL, S. N., MUKHERJEE, A., RUSSELL, R., RUEDA, O. M., ALESKANDARANY, M., GREEN, A. R., PROVENZANO, E., CALDAS, C., ELLIS, I. O. and RAKHA, E. A., 2015. Exploring Molecular Mechanisms Underlying Lymphovascular Invasion in Breast Cancer JOURNAL OF PATHOLOGY. 237, S19-S19
  • JOSEPH, C., CRAZE, M., SORIA, D., ELLIS, I. O. and MUKHERJEE, A., 2015. Role of Mitotic Checkpoint Proteins (BUB Family) in Breast Cancer JOURNAL OF PATHOLOGY. 237, S31-S31
  • CRAZE, M., JOSEPH, C., RUSSEL, R., RUEDA, O. M., PROVENZANO, E., CALDAS, C., ELLIS, I. O. and MUKHERJEE, A., 2015. SOCS2 as a Marker Related to Low Grade and Tumour Morphology in Breast Cancer JOURNAL OF PATHOLOGY. 237, S13-S13
  • CRAZE, M., JOSEPH, C., NOLAN, C., GREEN, A., RAKHA, E. A., ELLIS, I. O. and MUKHERJEE, A., 2015. Molecular Pathways Involved in Lymphovascular Invasion: A Biomarker Driven Approach JOURNAL OF PATHOLOGY. 237, S17-S17
  • MACNAMARA, O., JOSEPH, C., CRAZE, M., RAKHA, E. A., RUSSELL, R., RUEDA, O. M., PROVENZANO, E., CALDAS, C., ELLIS, I. O. and MUKHERJEE, A., 2015. MED7 in Breast Cancer: Relationship to Grade and Lymphovascular Invasion JOURNAL OF PATHOLOGY. 237, S31-S31
  • MUKHERJEE A, JOSEPH C, CRAZE M, CHRYSANTHOU E and ELLIS IO, 2015. The role of BUB and CDC proteins in low-grade breast cancers. Lancet (London, England). 385 Suppl 1, S72
  • ALESKANDARANY MA, SONBUL SN, MUKHERJEE A and RAKHA EA, 2015. Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. Pathobiology : journal of immunopathology, molecular and cellular biology. 82(3-4), 113-23
  • MUKHERJEE A and RAKHA E, 2013. Toward Personalized Breast Cancer Management: The Role of Lymphovascular Inva The Journal of Oncopathology. (In Press.)
  • MUKHERJEE A and RAKHA E, 2012. Integrating breast cancer genetics into clinical practice. Women's Health (Lond Engl). 8(1), 99-112
  • MUKHERJEE, A., SHEHATA, M., MOSELEY, P., RAKHA, E., ELLIS, I. and CHAN, S., 2010. Topo2α protein expression predicts the response to anthracycline combination neo-adjuvant chemotherapy in locally advanced breast cancer British Journal of Cancer. 103(12), 1794-1800
  • SHEHATA, M., MUKHERJEE, A., DEEN, S., AL-ATTAR, A., DURRANT, L.G. and CHAN, S., 2009. Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy British Journal of Cancer. 101, 1321-1328
  • MUKHERJEE A, MARTIN SG., 2008. The thioredoxin system: a key target in tumour and endothelial cells. British Journal of Radiology. Spec No 1, S57-68
  • MUKHERJEE A, HUBER K, EVANS H, LAKHANI N, MARTIN S, 2007. A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines. British Journal of Pharmacology. 151, 1167-1175
  • ULLENHAG G, MUKHERJEE A, WATSON NF, AL-ATTAR AH, SCHOLEFIELD JH, DURRANT LG, 2007. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer. Clinical Cancer Research. 13(17), 5070-5075
  • MARTIN SG, ORRIDGE C, MUKHERJEE A, MORGAN DA, 2007. Vascular endothelial growth factor expression predicts outcome after primary radiotherapy for head and neck squamous cell cancer Clin Oncol (R Coll Radiol). 19(1), 71-6
  • MUKHERJEE A, DHADDA AS, SHEHATA M AND CHAN S, 2007. Lapatinib: A Tyrosine Kinase Inhibitor (TKI) with a clinical role in Breast Cancer Expert Opinion in Pharmacotherapy. 8(13), 2189-204
  • SHEHATA M, A MUKHERJEE A, SHARMA R AND CHAN S, 2007. Liposomal doxorubicin in breast cancer Women’s Health (Lond Engl). 3(5), 557-69
  • MATHEW J, ASGEIRSSON KS, AGRAWAL A, MUKHERJEE A, ELLIS IO, CHEUNG KL, CHAN S, ROBERTSON JF, 2007. Neoadjuvant chemotherapy in locally advanced primary breast cancers - The Nottingham experience European Journal of Surgical Oncology. 33(8), 972-6
  • MUKHERJEE A AND MARTIN S, 2006. In vitro cytotoxicity of Phortress against colorectal cancer. International Journal of Oncology. 29(5), 1287-94
  • MUKHERJEE A, WESTWELL AD, BRADSHAW TD, STEVENS MF, CARMICHAEL J, MARTIN SG, 2005. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study British Journal of Cancer. 92(2), 350-8

School of Medicine

University of Nottingham
Medical School
Nottingham, NG7 2UH

Contacts: Call 0115 823 0031 ext.30031 or please see our 'contact us' page for further details